IBI323
IBI323 is a PD-L1/LAG-3 dual inhibitory antibody with Kd values of 0.0132 nM and 0.671 nM, respectively. IBI323 blocks the interaction of PD-L1 with PD-1 and CD80, as well as the interaction of LAG-3 with MHC-II. IBI323 mediates cross-linking of PD-L1-positive and LAG-3-positive cells, enhances T cell activation and cytokine secretion, and increases tumor-specific T cells in tumors and blood. IBI323 has a LALA mutation that reduces Fc-mediated effector function and inhibits tumor growth in humanized mouse models. IBI323 can be used for research on melanoma and colon cancer.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Species Reactivity
Human
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
39.75 nM
|
Blocking of LAG-3/MHC-II interaction in CHO cells overexpressing human MHC class II assessed by FACS after 30 min incubation at 4°C.
Blocking of LAG-3/MHC-II interaction in CHO cells overexpressing human MHC class II assessed by FACS after 30 min incubation at 4°C.
|
34239776 |
In Vitro
IBI323 (incubated at 4°C for 30 min) binds to CHO-S-hPD-L1 and 293-F-hLAG-3 cells with EC50 values of 4.74 nM and 1.25 nM, respectively[1].
IBI323 (incubated at 4°C for 30 min) binds activated primary human CD4+ T cells in a dose-dependent manner[1].
IBI323 (incubated at 4°C for 30 min) blocks PD-L1/PD-1 and PD-L1/CD80 interactions on CHO-S-hPD-L1 cells, with IC50 values of 23.99 nM and 14.96 nM, respectively[1].
IBI323 (incubated at 4°C for 30 min) blocks the LAG-3/MHC-II interaction with an IC50 of 39.75 nM[1].
IBI323 (6 h) activates LAG-3/MHC-II reporter Jurkat cells by blocking the LAG-3/MHC-II interaction[1].
IBI323 (incubated at 4°C for 30 min to room temperature for 1 h) mediates bridging between PD-L1+ MDA-MB-231 cells and LAG-3+ Jurkat T cells[1].
IBI323 (200 nM; 4 days) enhances IFN-γ and IL-2 secretion in a dose-dependent manner in human DC/CD4+ T cell mixed leukocyte reaction[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
IBI323 (3.5-11.6 mg/kg; intraperitoneal injection; on days 1, 7, 10, 13, and 16 after tumor cell implantation) significantly inhibited the growth of A375 melanoma in humanized NOG mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6-CD274tm1(hCD274)LAG3tm1(hLAG3) (female)[1]
-
Dosage:5.8 mg/kg; 1 mg/kg
-
Administration:i.p. on days 6, 10, 14, 17, and 21 post implantation
-
Result:Inhibited tumor growth in a dose-dependent manner.
Equalmolar IBI323 was more effective than IBI110 or Bi127 monotherapy, resulting in a cure rate of 80%.
On day 21, IBI323-treated mice showed a significant reduction in tumor volume relative to the IgG group.
-
Animal Model:NOG (strain: 408; female)[1]
-
Dosage:3.5 mg/kg; 11.6 mg/kg
-
Administration:i.p. on days 1, 7, 10, 13, and 16 after tumor cell implantation
-
Result:Significantly inhibited A375 tumor growth at both 3.5 mg/kg and 11.6 mg/kg doses.
Target
LAG-3 & PD-L1
Conjugated
Unconjugated
Application
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[IBI323]
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
IBI323 Related Classifications
HY-P992546 Related Classifications
Powered by Bioz